Beginners’ Portfolio: What Have Vodafone Group plc, GlaxoSmithKline plc And Barclays PLC Done For Our Blue-Chip Prospects?

How did blue-chip purchases of Vodafone Group plc (LON: VOD), GlaxoSmithKline plc (LON: GSK) and Barclays PLC (LON: BARC) pan out?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article is the latest in a series that aims to help novice investors with the stock market. To enjoy past articles in the series, please visit our full archive.

The Beginners’ Portfolio is a virtual portfolio, run as if based on real money with all costs, spreads and dividends accounted for. Transactions made for the portfolio are for educational purposes only and do not constitute advice to buy or sell.

When I started the Beginners’ Portfolio my intention was to go for a combination of blue-chip dividend-paying shares and growth shares, and the success so far has been mixed with both approaches. Today I’m going to look at the blue-chip portion of the portfolio, paying special attention to one share I’ve since sold and two I still keep.

Telecoms profit

I sold Vodafone (LSE: VOD) back in December 2013 at a price of 234p, mainly because I thought its undervaluation was out by then, and partly because voice revenues were falling and I didn’t see a clear forward strategy for the company. As it happened, the timing worked out pretty well, and the portfolio made a capital gain of £166.46 with dividends of £58.35 added to the pot — a very nice overall gain of 45% over a 19-month period, after accounting for all costs.

Since then the price has been erratic and today is a little higher at 244p, but I think I made the right decision at the time.

Pharma laggard

GlaxoSmithKline (LSE: GSK) has not worked out as well as I thought it would have by now since I bought it in June 2012. In fact, if I sold at today’s 1,409p level I’d realise a loss on the share price of 6.6% — although total dividends of £79.56 would swing that to a modest total 9.2% gain after costs.

I thought the prospects of a return to earnings growth in 2016 would have improved sentiment towards Glaxo by now, but until that happens I’m happy to hold and keep taking dividend yields of around 6%.

Banking on banking

As the banking sector returned to health, I decided I wanted one to help give us a balanced portfolio, and I went for Barclays (LSE: BARC) in February 2014. Since then we’ve enjoyed a 6.7% gain (after costs) from a share price rise to 282p, with £15.75 in dividends taking the total gain to 9.6%.

One of my big reasons for choosing Barclays was its recovering dividend. It only yielded 2.7% in 2014 but it was very well covered. And we have EPS growth of around 33% forecast for this year, followed by another 20% in 2016, which makes me think we’re still in early days of Barclays’ recovery — and it was a good time to get in.

Bottom line

How has the blue-chip portion of the portfolio performed overall? I couldn’t finish without mentioning the overall 18% loss I took when I dumped Tesco, eased a little by some dividends in the early days. BP has been pretty flat with a total return of 2.8%, Rio Tinto is disappointingly down 13%, again softened by decent dividends, BAE Systems is sitting pretty with a very nice 54% overall gain, and Aviva has given us an even better 74% gain so far.

The blue-chip portion of the portfolio is up 16% after considering the effects of all costs (including the cost of selling the whole lot today). For an average holding time of around a couple of years, that compares reasonably well to the 10% or so we’d have gained from a FTSE 100 tracker over a similar period.

Next time I’ll take a look at the portfolio’s growth stocks.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended Barclays and GlaxoSmithKline, and owns shares in Tesco. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

P/Es below 7! 3 staggeringly cheap shares despite yesterday’s rally

Investors who fear they have missed their opportunity to buy cheap shares as the stock market recovers might want to…

Read more »

ISA coins
Investing Articles

Want to know what UK investors have been buying in their ISAs?

Looking for stock, trust, and fund ideas this April? Royston Wild discusses what Brits have been stuffing in their Stocks…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Why aren’t people buying Greggs shares by the bucketload?

Greggs' shares remain in the doldrums. But should Foolish investors consider pouncing while others won't? Paul Summers takes a fresh…

Read more »

Picture of an easyJet plane taking off.
Investing Articles

£10,000 invested in easyJet shares 2 days ago is now worth…

easyJet shares just experienced a sharp move higher. So anyone who invested in the budget airline operator two days ago…

Read more »

Wall Street sign in New York City
Investing Articles

I’m getting ready for a dramatic stock market crash

Our writer sees plenty of reasons that could mean a lot of stock market volatility is on the way. But…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£5,000 invested in BP shares 2 days ago is now worth…

BP shares were in a very strong upward trend. However, in the last few days they have pulled back amid…

Read more »

A young black man makes the symbol of a peace sign with two fingers
Investing Articles

2 top FTSE 250 investment trusts to consider in April

The FTSE 250 is brimming with high-quality investment trusts. Our writer highlights two very different options, including a mid-cap newcomer.

Read more »

Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower
Investing Articles

After making a fortune on Tesla, this FTSE 250 trust has piled into a little-known S&P 500 stock

Baillie Gifford made huge profits from S&P 500 growth stocks like Nvidia. Lately, it's been snapping up a lesser-known tech…

Read more »